enfortumab vedotin,pembrolizumab,avelumab,gemcitabine,carboplatin
merck,pfizer,astellas,seagen
['ev-302', 'muc ,(-much)', 'blcsm', 'avelumab', 'pembro']
to me the ev+pembro pfs data are very compelling. if ev+pembro is approved (before the ev-302 readout), i'd be inclined to favor ev+pembro over gem+carbo -&gt; avelumab for my cis-ineligible muc pts. what do you think ? #esmo22 #blcsm 
Medical Oncologist @TexasOncology & @TheUSONetwork - focused on GU cancers and clinical trials - former fellow @MSKCancerCenter - tweets are my own